linjc16/ctgov huggingface dataset:
Validation of the Zigzag Tracking Task Test for the Evaluation of Handwriting Difficulties in Writer's Cramp

Study Overview
=================
Brief Summary
-----------------
Writer's cramp (WC) is a task specific dystonia that occurs from the moment patient starts writing. It leads to partial or complete inability to use the hand only during the handwriting gesture. It is characterized by the appearance of cramps or spasms of certain muscles of the hand and/or forearm. Clinical scales currently use for the assessment of WC fail to accurately reflect changes in the characteristics of handwriting in response to treatments (Botulinum Neurotoxin injections and / or retraining therapy). The Zigzag Tracking Task (ZZTT), easy to use in current practice provides useful information in terms of speed and precision of handwriting gesture. This timed handwriting test is to follow with a pen a zigzag path beset with obstacles to avoid. It permits to evaluate the time in seconds required to carry out the zigzag path and count the number of errors (output path and contacts with obstacles). The investigators propose to validate the ZZTT for the assessment of the handwriting gesture of WC.

Conditions
-----------------
Dystonic Disorder

Intervention / Treatment
-----------------
* Other: Validation of a handwriting scale


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: scholarship in French language, at least until 16 years old writer's cramp (diagnostic confirmed by a neurologist specialized in movement disorders) prescription of botulinum neurotoxin injection prescription de novo or absence of injection in the last 3 months informed consent medical insurance coverage Exclusion Criteria: writing tremor -other neurological disease with effect on handwriting pain or traumatism of the upper limb, with effect on handwriting non-corrected visual disturbances patient living outside the region where the study will be held (Ile-de-France) participation in another research with a potential impact on evaluation criteria pregnant or breast feeding patient patient under judiciary protection

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| writer's cramp<br>patients assessed without, then with Botulinum Neurotoxin injections | Other: Validation of a handwriting scale<br> <br> |
| control<br>age and gender matched | Other: Validation of a handwriting scale<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| hand-writing speed | speed and accuracy of handwriting | immediate |
Characteristics of TraceTogether Users

Study Overview
=================
Brief Summary
-----------------
In this protocol, we seek the understand the demographics of individuals who have used the TraceTogether mobile application. Little is known about the group of individuals who are more likely to utilise the application. Hence, this study hopes to: (1) Understand the demographics of Singaporeans who use and do not use TraceTogether, (2) Identify other behavioural habits of people who do use TraceTogether, (3) Determine if confidence in government would have any effect on TraceTogether usage

Official Title
-----------------
Characteristics of TraceTogether Users

Conditions
-----------------
Coronavirus

Intervention / Treatment
-----------------
* Behavioral: Use of mobile application


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: At least 21 years Has stayed in Singapore for at least 2 years Exclusion Criteria: Below 21 years Has stayed in Singapore for less than 2 years

Ages Eligible for Study
-----------------
Minimum Age: 21 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Community sample<br>We plan to recruit a representative sample of the Singapore population. | Behavioral: Use of mobile application<br>* Use of the TraceTogether mobile application during the COVID-19 period<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Demographic information | Age, gender, social economic status | Once during initial enrolment | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Contact tracing, TraceTogether, COVID-19
Characterizing Ankle Function During Sloped Locomotion for Prosthesis Development

Study Overview
=================
Brief Summary
-----------------
The proposed study aims to characterize biological ankle joint function during walking and running on slopes in order to further develop advanced powered ankle-foot prostheses. Ankle joint torque and angle data will be collected from non-amputees while walking and running at multiple speeds and slopes. This data will be used to develop control parameters for a powered ankle-foot prosthesis. Then, these parameters will be implemented and tested in a powered prosthesis worn by people with below the knee amputations.

Official Title
-----------------
Characterizing Ankle Function During Sloped Locomotion for Prosthesis Development

Conditions
-----------------
Traumatic Amputation of Lower Extremity

Intervention / Treatment
-----------------
* Device: Powered ankle-foot prosthesis


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Study 1: - Between 18-60 years old. Study 2 and 3: Between 18-60 years old. At least 1 year post-amputation no current problems with prosthesis or residual limb At least a K3 level of ambulation Study 4: - Between 18-45 years old Study 5: Between 18-45 years old At least 1 year post-amputation no current problems with prosthesis or residual limb Experience running with a passive prosthesis At least a K4 level of ambulation Exclusion Criteria: Studies 1-5 Cardiovascular, pulmonary, or neurological disease or disorder Musculoskeletal injury

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Non-amputee<br>People without an amputation will be recruited to participate in the study. | |
| Below the knee amputee<br>People with a unilateral transtibial amputation will be recruited to participate in the study. | Device: Powered ankle-foot prosthesis<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Force-measuring treadmill and motion capture |  | approximately 2 months | 
| Metabolic analysis system |  | approximately 2 months |
Detection of Cancer-Specific Active Proteases in Blood Via Fluorescence

Study Overview
=================
Brief Summary
-----------------
The primary objective is to develop a rapid in vitro screening assay for detection of pancreatic cancer biomarkers in blood of patients with pancreatic cancer.

Detailed Description
-----------------
The goal of the project is to develop a rapid in vitro screening assay for detection of cancer biomarkers in blood. The aim is testing and optimization of nanoparticle sensors, based on cyanine dyes that are chemically linked to Fe/Fe3O4 nanoparticles via protease-selective consensus (cleavage) sequences. The focus is on the quantitative determination of active cancer-specific proteases in blood via simple fluorescence measurements. The matrix metalloproteinases, urokinase-type plasminogen activator, and cathepsins, are up-regulated in the vast majority of progressing cancers and can, therefore, serve as markers for cell survival/tumor progression, angiogenesis, and tissue remodeling/invasion

Official Title
-----------------
Detection of Cancer-Specific Active Proteases in Blood Via Fluorescence

Conditions
-----------------
Pancreatic Cancer

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Inclusion Criteria for Pancreatic Cancer Patients: Patients will either have a histologic diagnosis of pancreatic carcinoma or a clinical picture consistent with pancreatic cancer and will be undergoing surgery or a diagnostic procedure to confirm the diagnosis. Patients will have had no prior treatment or surgery Inclusion Criteria for Healthy Subjects: Subjects will have no prior history of any cancer Exclusion Criteria: Exclusion Criteria for Pancreatic Cancer Patients Any prior treatment for pancreatic cancer Poorly controlled diabetes Exclusion Criteria for Healthy Subjects Poorly controlled diabetes

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| pancreatic cancer<br>This study will collect blood from 36 patients with known or suspected pancreatic cancer and from 12 healthy cancer-free subjects. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
pancreatic cancer, nanoparticle, proteases, cell survival, tumor progression, angiogenesis, tissue remodeling/invasion
Verification of Imaging System PCD-1000A

Study Overview
=================
Brief Summary
-----------------
Scope Verification of technologies included in the PCD-1000A PET/CT imaging chain. Define and confirm all supported clinical protocols Evaluate performance

Detailed Description
-----------------
The study aim is system verification and associated software. Clinical data and clinical feedback will be used for verification.

Official Title
-----------------
Verification of Imaging System PCD-1000A

Conditions
-----------------
Cancer Patients

Intervention / Treatment
-----------------
* Device: PET/CT imaging


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients already scheduled for an FDG test at SDMI 40 years and older Capable of providing their informed consent Exclusion Criteria: Patients not scheduled for an FDG test at SDMI 39 years or younger Adult female patients that are and/or could become pregnant Not capable of providing their informed consent

Ages Eligible for Study
-----------------
Minimum Age: 40 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Patients already scheduled for a FDG test<br>Subjects will be selected from patients already scheduled for a routine FDG PET/CT test. Only adult patients, 40 years old or older, capable of providing their informed consent, will be selected. Any adult female patients that are pregnant and/or could become pregnant will be excluded. Twenty patients will be recruited. | Device: PET/CT imaging<br>* Subjects will be have a PET/CT scan with PCD-1000A following their scheduled routine PET/CT scan. There will be no additional administration of radiopharmaceutical for the study.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Confirm that PCD-1000A PET/CT System is Effective for Its Intended Use | PCD-1000A PET/CT system's performance will be evaluated for oncology PET imaging on cancer patients to verify that the system performs as expected. • Verify that all supported clinical protocols from PET acquisition, reconstruction, to presentation (filtering) perform as expected. Images acquired by PCD-1000A PET/CT will be compared with images acquired during a standard-of-care PET/CT scan by a commercially available PET/CT system just prior to imaging with the PCD-1000A PET/CT System. Image quality evaluation will include assessment of uniformity of the liver, delineation of the lungs, presence of artifacts and using Likert scale. | 3 months |
Local Anesthetics After Total Knee Arthroplasty

Study Overview
=================
Brief Summary
-----------------
The aim of this randomized, double-blind and placebo-controlled study is to evaluate the specific role of injection of local anesthetic into the intra- vs. extraarticular tissues after toal knee arthroplasty.

Official Title
-----------------
Local Anesthetics After Total Knee Arthroplasty: Intra- vs. Extraarticular Administration? A Randomized, Double-Blind, Placebo-Controlled Study

Conditions
-----------------
Postoperative Pain

Intervention / Treatment
-----------------
* Procedure: local infiltration analgesia


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Able to give informed oral and written consent to participate Able to speak Danish Exclusion Criteria: Treatment with opioids Body Mass Index > 40

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple


Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: local infiltration analgesia|local wound infiltration with 30 ml ropivacaine 0.2 % (60 mg)|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Visual Analogue Scale pain score |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
pain, local infiltration analgesia
Bilateral vs. Unilateral Erector Spinae Plane Block

Study Overview
=================
Brief Summary
-----------------
The importance of multimodal analgesia for postoperative pain management is well known and regional anesthesia techniques are commonly prefferred to provide better analgesia. Erector spinae plane block (ESB) is a new defined and effective regional anesthesia technique. But two injections can be unconfortable for some patients. With this study, we aimed to compare the analgesia effect of bilateral and unilateral ESP block for laparoscopic cholecystectomy.

Official Title
-----------------
Bilateral vs. Unilateral Erector Spinae Plane Block for Laparoscopic Cholecystectomy; A Randomised Controlled Trial

Conditions
-----------------
Postoperative Pain, Cholecystitis; Gallstone

Intervention / Treatment
-----------------
* Procedure: Bilateral ESP Block
* Procedure: Unilateral ESP Block
* Device: Intravenous Morphine patient controlled analgesia device


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: ASA I-II patients Pateints undergoing elective laparoscopic cholecystectomy Exclusion Criteria: obesity (body mass index >35 kg/m2) infection of the skin at the site of needle puncture area patients with known allergies to any of the study drugs coagulopathy recent use of analgesic drugs

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Bilateral<br>Bilateral ESP block will be performed | Procedure: Bilateral ESP Block<br>* Bilateral ESP Block will be performed at T8<br>Device: Intravenous Morphine patient controlled analgesia device<br>* 24 hour morphine consumption will be recorded<br>|
| Active Comparator: Unilateral<br>Unilateral ESP block will be performed | Procedure: Unilateral ESP Block<br>* Unilateral ESP Block will be performed at T8 (right side)<br>Device: Intravenous Morphine patient controlled analgesia device<br>* 24 hour morphine consumption will be recorded<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Morphine consumption | Morphine consumption will be recorded | preoperative 24th hour | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Numeric Rating Scale | A NRS involves asking the patient to rate his or her pain from 0 to 10 (11 point scale) with the understanding that 0 is equal to no pain and 10 is equal to worst possible pain. | postoperative 24th hour | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
erector spinae plane block, postoperative pain, laparoscopic cholecystectomy
Kor PCI - CAD Patients Treated With PCI: Analysis of the Korean Nationwide Health Insurance Database

Study Overview
=================
Brief Summary
-----------------
Current Status and Prognosis of Coronary artery disease patients treated with coronary intervention - Analysis of the Korean Nationwide Health Insurance Database

Detailed Description
-----------------
This is a retrospective study and is conducted for all patients who received percutaneous coronary intervention among cohorts registered with the National Health Insurance Service. Primary outcome is all cause of mortality. Secondary outcomes are cardiovascular death, ischemic stroke, cerebral hemorrhage, admission due to gastrointestinal bleeding, and admission due to major bleedings.

Official Title
-----------------
Coronary Artery Disease Patients Treated With Percutaneous Coronary Intervention: Analysis of the Korean Nationwide Health Insurance Database

Conditions
-----------------
Coronary Artery Disease, Drug-eluting Stents, Drug-coated Balloon

Intervention / Treatment
-----------------
* Device: drug-eluting stent
* Device: drug-coated balloon


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All coronary artery disease patients wih Korean NHIS (National Health Insurance Service)-listed PCI Exclusion Criteria: non-specified

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Device: drug-eluting stent|A group of percutaneous coronary intervention (PCI) using drug-eluting stents (DES)|
|Device: drug-coated balloon|A group of percutaneous coronary intervention (PCI) using drug-coated balloon (DCB)|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| All cause of death | 'All cause of death' will be recorded as number of participants with 'All cause of death' | 10 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Cardiovascular death | 'Cardiovascular death' will be recorded as number of participants with 'Cardiovascular death' | 10 years | 
| ischemic stroke | 'ischemic stroke' will be recorded as number of participants with 'ischemic stroke' | 10 years | 
| Cerebral hemorrhage | 'Cerebral hemorrhage' will be recorded as number of participants with 'Cerebral hemorrhage' | 10 years | 
| Admission due to gastrointestinal bleeding | 'Admission due to gastrointestinal bleeding' will be recorded as number of participants with 'Admission due to gastrointestinal bleeding' | 10 years | 
| Admission due to major bleeding | 'Admission due to major bleeding' will be recorded as number of participants with 'Admission due to major bleeding' Thismeasure is a composite outcome, which includes cerebral hemorrhage, admission due to gastrointestinal bleeding. | 10 years |
HYZAAR vs. Ramipril for Diabetes (0954A-245)(COMPLETED)

Study Overview
=================
Brief Summary
-----------------
A study to test the safety and efficacy of HYZAAR as compared to Ramipril in patients with type 2 diabetes mellitus (high blood sugar) and hypertension (high blood pressure).

Official Title
-----------------
HYZAAR Versus Ramipril Diabetic Patients

Conditions
-----------------
Type 2 Diabetes Mellitus, Hypertension

Intervention / Treatment
-----------------
* Drug: MK0954A, losartan potassium (+) hydrochlorothiazide (HYZAAR) / Duration of Treatment : 8 Weeks
* Drug: Comparator : ramipril /Duration of Treatment : 8 Weeks


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient is at least 18 years old, has been diagnosed with type 2 diabetes mellitus Exclusion Criteria: Patient has renal disease, malignant hypertension, uncontrolled type 2 diabetes mellitus, history of stroke, TIA (Transient Ischemic Attacks) , or heart disease

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: MK0954A, losartan potassium (+) hydrochlorothiazide (HYZAAR) / Duration of Treatment : 8 Weeks|nan|
|Drug: Comparator : ramipril /Duration of Treatment : 8 Weeks|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To determine the antihypertensive effectiveness of HYZAAR as compared to Ramipril as measure by SiSBP at Week 4 |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To determine the safety anf tolerability of HYZAAR as compared to Ramipril as seen in overall adverse experiences for the duration of the study |  |  |